{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T10:11:54Z","timestamp":1790331114495,"version":"4.1.0"},"reference-count":66,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Simplivia Healthcare, Ltd."},{"DOI":"10.13039\/100007535","name":"B. Braun Medical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007535","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      The European Biosafety Network recommends that cytotoxic drug surface contamination in pharmacies and patient wards not exceed 0.1 ng\/cm\n                      <jats:sup>2<\/jats:sup>\n                      . Among other mitigations, closed system transfer devices (CSTDs) are recommended in the US, Europe, and UK for the reduction of surface contamination. Although in the UK CSTDs are not part of standard cytotoxic preparation procedures in isolators, CSTD syringe adaptors are recommended for use with syringes for intravenous administration. We investigated whether the addition of a CSTD syringe adaptor in the isolator reduces cytotoxic residue contamination during intravenous bolus administration.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Twenty-five cyclophosphamide syringes were prepared with hub caps and twenty-five with SIMPLIVIA\n                      <jats:sup>\u00ae<\/jats:sup>\n                      (formerly Tevadaptor\/OnGuard\n                      <jats:sup>\u00ae<\/jats:sup>\n                      ) Syringe Adaptor Locks (SALs) in an isolator. Surface contamination of syringes, gauze pads placed at the administration site, and nurses\u2019 gloves was compared between the practice of connecting hub caps in the isolator and removing them in the ward versus connecting SALs in the isolator during preparation. Cyclophosphamide contamination was quantified by liquid-chromatography mass spectrometry.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Use of SALs compared to standard hub caps led to statistically significant reduction in cyclophosphamide contamination on the syringes (2.41\u2009\u00b1\u20090.89 ng versus 33.42\u2009\u00b1\u20098.48 ng, p\u2009=\u20090.0007), the swabs used for connect\/disconnect (0.01372\u2009\u00b1\u20090.01 ng versus 655.80\u2009\u00b1\u2009190.18 ng, p\u2009=\u20090.001), and nurses\u2019 gloves (0.0009\u2009\u00b1\u20090.0009 ng versus 8.31\u2009\u00b1\u20093.94 ng, p\u2009=\u20090.04). When hub caps were used, 48% of syringes, 76% of gauze pads, and 8% of gloves exceeded the recommended limit of 0.1 ng\/cm\n                      <jats:sup>2<\/jats:sup>\n                      , while no samples exceeded this limit with SAL.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The implementation of CSTD syringe adaptors was beneficial for reducing cytotoxic drug exposure to nurses administering intravenous syringes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552251334027","type":"journal-article","created":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T15:18:00Z","timestamp":1745421480000},"page":"1266-1273","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["Evaluation of the effect of closed system transfer device syringe adaptor connection in the isolator on cytotoxic residue contamination during intravenous administration"],"prefix":"10.1177","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-1644-3769","authenticated-orcid":false,"given":"Louisa","family":"Knowles","sequence":"first","affiliation":[{"name":"Faculty of Medical and Human Sciences, University of Manchester, Manchester, UK"},{"name":"University Hospitals Birmingham NHS Foundation Trust"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,4,23]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1529"},{"key":"e_1_3_3_3_2","unstructured":"HSE. Safe handling of cytotoxic drugs in the workplace. Health and Safety Executive. https:\/\/www.hse.gov.uk\/healthservices\/safe-use-cytotoxic-drugs.htm."},{"key":"e_1_3_3_4_2","article-title":"ISOPP Standards for the safe handling of cytotoxics","volume":"28","author":"Standards I","year":"2022","unstructured":"Standards I. ISOPP Standards for the safe handling of cytotoxics. J Oncol Pharm Pract 2022; 28: S1\u2013S126.","journal-title":"J Oncol Pharm Pract"},{"key":"e_1_3_3_5_2","unstructured":"USP. USP General Chapter <800> Hazardous Drugs\u2013 Handling in Healthcare Settings 2020. https:\/\/www.usp.org\/."},{"key":"e_1_3_3_6_2","unstructured":"Practice ACoP. ASHP Guidelines on Handling Hazardous Drugs. Drug Distribution and Control: Preparation and Handling\u2013Guidelines 2018."},{"key":"e_1_3_3_7_2","first-page":"1881","article-title":"Risk of handling injectable antineoplastic agents","volume":"39","author":"Anderson RW","year":"1982","unstructured":"Anderson RW, Puckett Jr WH, Dana WJ, et al. Risk of handling injectable antineoplastic agents. Am J Hosp Pharm 1982; 39: 1881\u20131887.","journal-title":"Am J Hosp Pharm"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.56.6.354"},{"key":"e_1_3_3_9_2","unstructured":"Preventing Occupational Exposures to Antineoplastic and Other Hazardous Drugs in Health Care Settings 2004."},{"key":"e_1_3_3_10_2","unstructured":"HSE\/MHRA. Handling Cytotoxic Drugs in Isolators in NHS Pharmacies. Health and Safety Executive and Medicines and Healthcare Products Regulatory Authority."},{"key":"e_1_3_3_11_2","unstructured":"EBN. Amendments to the Carcinogens and Mutagens Directive on Hazardous Drugs and Implications for Change to the Heathcare System in Europe to Ensure Compliance with its Requirements 2019. https:\/\/www.europeanbiosafetynetwork.eu\/wp-content\/uploads\/2019\/03\/Amendments-to-CMD3-and-implications.pdf."},{"key":"e_1_3_3_12_2","unstructured":"NHS. Guidance on Handling of Injectable Cytotoxic Drugs in Clinical Areas in NHS Hospitals in the UK. NHS Pharmaceutical Quality Assurance Committee 2022."},{"key":"e_1_3_3_13_2","volume-title":"Ensuring Healthcare Worker Safety When Handling Hazardous Drugs","author":"ONS\/HOPA","year":"2019","unstructured":"ONS\/HOPA. Ensuring Healthcare Worker Safety When Handling Hazardous Drugs. Pittsburgh: The Oncology Nursing Society and Hematology\/Oncology Pharmacy Association, 2019."},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00420-021-01731-w"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/nop2.1853"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/JOM.0000000000000249"},{"key":"e_1_3_3_17_2","unstructured":"IARC. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Some Antiviral and Antineoplastic Drugs and Other Pharmaceutical Agents. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans No 76. International Agency for Research on Cancer 2000."},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)93148-I"},{"key":"e_1_3_3_19_2","first-page":"855","article-title":"Leukaemia and reproductive outcome among nurses handling antineoplastic drugs","volume":"49","author":"Skov T","year":"1992","unstructured":"Skov T, Maarup B, Olsen J, et al. Leukaemia and reproductive outcome among nurses handling antineoplastic drugs. Br J Ind Med 1992; 49: 855\u2013861.","journal-title":"Br J Ind Med"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15041334"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.5271\/sjweh.1433"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01616"},{"key":"e_1_3_3_23_2","unstructured":"EU-OSHA. Directive 2004\/37\/EC of the European Parliament and of the Council of 29 April 2004 on the protection of workers from the risks related to exposure to carcinogens mutagens or reprotoxic substances at work. European Agency for Health and Safety at Work. https:\/\/eur-lex.europa.eu\/eli\/dir\/2004\/37\/oj\/eng."},{"key":"e_1_3_3_24_2","unstructured":"HSE. Control of substances hazardous to health. The Control of Substances Hazardous to Health Regulations 2002 (as amended). Approved Code of Practice and guidance. L5 (Sixth edition) Health and Safety Executive 2013."},{"key":"e_1_3_3_25_2","unstructured":"Health and Safety at Work etc. Act. Legislation.gov.uk 2022. https:\/\/www.legislation.gov.uk\/ukpga\/1974\/37\/contents."},{"key":"e_1_3_3_26_2","unstructured":"The Management of Health and Safety at Work Regulations. Legislation.gov.uk 2022. https:\/\/www.legislation.gov.uk\/uksi\/1999\/3242\/regulation\/29\/made."},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01616"},{"key":"e_1_3_3_28_2","unstructured":"ASSTSAS. Prevention Guide Safe Handling of Hazardous Drugs 2008. http:\/\/asstsas.qc.ca\/sites\/default\/files\/publications\/documents\/Guides_Broch_Depl\/GP65A_hazardous_drugs.pdf."},{"key":"e_1_3_3_29_2","unstructured":"OSHA. Occupational Safety and health Standards for Toxic and Hazardous Substances 1910.1200 Hazard Communication. Occupational Safety and Health Administration 2022. https:\/\/www.osha.gov\/laws-regs\/interlinking\/standards\/1910.1200\/regulations."},{"key":"e_1_3_3_30_2","unstructured":"OSHA. Hazardous Drugs - 1910.1020 Access to Employee Exposure and Medical Records. Occupational Safety and Health Administration 2022. https:\/\/www.osha.gov\/hazardous-drugs\/standards."},{"key":"e_1_3_3_31_2","unstructured":"NIOSH. Preventing occupational exposures to antineoplastic and other hazardous drugs in health care settings 2004."},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2020.10.047"},{"key":"e_1_3_3_33_2","unstructured":"USP. Chapter <800>: Hazardous drugs\u2014handling in healthcare settings. The United States Pharmacopeia 39th rev and The National Formulary 34th ed First supplement US Pharmacopeial Convention 2016."},{"key":"e_1_3_3_34_2","unstructured":"Health NIOSH. Closed System Drug-Transfer Device (CSTD) Research. Centers for Disease Control and Prevention."},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp160948"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155212468367"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155211401454"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp050258"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/59.1.68"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1186\/2193-1801-2-273"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1310\/hpj4203-219"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1177\/001857879903401110"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155210361431"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1310\/hpj4803-204"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155209352543"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0159052"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1177\/107815520100600403"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155214544993"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155213498630"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/60.22.2314"},{"key":"e_1_3_3_51_2","first-page":"153","article-title":"Use of a closed system device to reduce occupational contamination and exposure to antineoplastic drugs in the hospital work environment","volume":"53","author":"Yoshida J","year":"2009","unstructured":"Yoshida J, Tei G, Mochizuki C, et al. Use of a closed system device to reduce occupational contamination and exposure to antineoplastic drugs in the hospital work environment. Ann Occup Hyg 2009; 53: 153\u2013160.","journal-title":"Ann Occup Hyg"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155213517127"},{"key":"e_1_3_3_53_2","first-page":"36","article-title":"Evaluation of two closed-system drug transfer device in the antineoplastic drug elaboration process","volume":"40","author":"G\u00f3mez-\u00c1lvarez S","year":"2016","unstructured":"G\u00f3mez-\u00c1lvarez S, Porta-Oltra B, Hernandez-Griso M, et al. Evaluation of two closed-system drug transfer device in the antineoplastic drug elaboration process. Farm Hosp 2016; 40: 36\u201343.","journal-title":"Farm Hosp"},{"key":"e_1_3_3_54_2","unstructured":"Sewell G. Application of a published study on stability\/compatibility data for cytotoxic drugs with the Tevadaptor device to cytotoxic drugs (non biological) outside the study: Expert Commentary 2020."},{"key":"e_1_3_3_55_2","unstructured":"Santillo M. Review of Drug Compatibility with the Tevadaptor System 2020."},{"key":"e_1_3_3_56_2","first-page":"26","article-title":"Studies on the stability and compatibility of cytotoxic drug infusions with the tevadaptor device","volume":"8","author":"Sewell G","year":"2014","unstructured":"Sewell G, Massimini M. Studies on the stability and compatibility of cytotoxic drug infusions with the tevadaptor device. European Journal of Oncology Pharmacy 2014; 8: 26\u201330.","journal-title":"European Journal of Oncology Pharmacy"},{"key":"e_1_3_3_57_2","unstructured":"Wilkinson A-S. Drug sterility is maintained in Luer Lock (LL) syringes fitted with Tevadaptor syringe adaptor lock (SAL) according to NHS yellow cover document (YCD syringe integrity standards 2022."},{"key":"e_1_3_3_58_2","unstructured":"Braun B. Tevadaptor\u00ae closed system transfer device 2023. https:\/\/www.bbraun.co.uk\/en\/products-and-therapies\/infusion-therapy\/tevadaptor-.html."},{"key":"e_1_3_3_59_2","doi-asserted-by":"publisher","DOI":"10.12968\/bjon.2020.29.10.S15"},{"key":"e_1_3_3_60_2","volume-title":"Quality Assurance of Aseptic Preparation Services: Standards.","author":"Beaney A","year":"2016","unstructured":"Beaney A. Quality Assurance of Aseptic Preparation Services: Standards. 5th Edition. Royal Pharmaceutical Society and the NHS Pharmaceutical Quality Assurance Committee, 2016.","edition":"5"},{"key":"e_1_3_3_61_2","unstructured":"Group PAS. Guidance for Syringe Maximum Fill Volumes in NHS Pharmacy Aseptic Services 2023. https:\/\/portal.uhb.nhs.uk\/Citrix\/UHBInternalWeb\/clients\/HTML5Client\/src\/SessionWindow.html?launchid=1677413894768."},{"key":"e_1_3_3_62_2","unstructured":"Committee NPQA. Protocols for the integrity testing of syringes 2022."},{"key":"e_1_3_3_63_2","unstructured":"Committee NPQA. End of Session Broth Fill Technique for Sterility Assurance of Products Aseptically Prepared in Section 10 Units 2023. https:\/\/www.sps.nhs.uk\/wp-content\/uploads\/2010\/05\/Broth20Fill20Techinque20Aseptically20Prepared20Section2010.pdf."},{"key":"e_1_3_3_64_2","unstructured":"Cytotoxic Residue Monitoring. 2022."},{"key":"e_1_3_3_65_2","unstructured":"Pharmacopoeia B. Appendix III D. Liquid Chromatography 2023. https:\/\/www-pharmacopoeia-com.manchester.idm.oclc.org\/bp-2023\/appendices\/appendix-03\/appendix-iii-d\u2013liquid-chromatography.html?date=2023-04-01&timeline=True."},{"key":"e_1_3_3_66_2","unstructured":"NASA. Anthropometry and Biomechanics. Volume 1 Section 3. National Aeronautics and Space Administration. Updated 27 February 2024. Accessed 19 May2024 https:\/\/msis.jsc.nasa.gov\/sections\/section03.htm."},{"key":"e_1_3_3_67_2","doi-asserted-by":"publisher","DOI":"10.4212\/cjhp.v68i2.1435"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552251334027","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552251334027","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552251334027","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T09:56:49Z","timestamp":1790330209000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552251334027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,23]]},"references-count":66,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1177\/10781552251334027"],"URL":"https:\/\/doi.org\/10.1177\/10781552251334027","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,23]]}}}